双重打击淋巴瘤(DHL)通常是指发生MYC基因重排,同时伴有bcl-2和(或)bcl-6基因重排的大B细胞淋巴瘤.DHL侵袭性强,常规方案治疗预后差,目前尚无标准的一线治疗方案.文章就DHL在诊断、生物学行为、预后影响因素和治疗方面的研究进展进行综述,旨在加深对DHL的理解,优化治疗策略,以期改善其预后.
"Double-hit"; lymphoma is usually defined to be large B-cell lymphoma with MYC gene rearrangement combined with bcl-2 and/or bcl-6 gene rearrangement.It is highly aggressive with poorer prognosis after R-CHOP treatment and so far,its optimal therapy has not been developed.This article reviewed new advances in diagnosis,biology,prognostic factors and treatment of DHL in order to deepen insights,optimize therapy and improve prognosis of DHL.